Modified-released oral opioids
- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
Table of contents
Overview
Outcome of a procedure under Article 31 of Directive 2001/83/EC as amended
The European Medicines Agency has completed a review of the safety and effectiveness of modified-release oral opioid medicines of the WHO level III scale for the management of pain. The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of most of these medicines continue to outweigh their risks, but that warnings on the use of these medicines together with alcohol should be made consistent across the class.
However, for modified-release medicines that contain a 'polymethacrylate-triethylcitrate controlled release system', the Committee concluded that the marketing authorisations should be suspended. These suspensions will remain in force until the companies that make these medicines have reformulated them so that they are more stable in alcohol.
After re-examination, the Committee confirmed these recommendations on 18 November 2010.
Key facts
About this medicine
|
|
---|---|
Approved name |
Modified-released oral opioids
|
International non-proprietary name (INN) or common name |
|
Class |
Opioids of the World Health Organization level III scale
|
About this procedure
|
|
---|---|
Current status |
European Commission final decision
|
Reference number |
EMEA/H/A-31/001232
|
Type |
Article 31 referrals
This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines. |
Key dates and outcomes
|
|
---|---|
CHMP opinion date |
18/11/2010
|
EC decision date |
20/04/2011
|
All documents
Assessment Report for Authorised modified-release oral medicinal products of the WHO level III scale for the management of pain (intense sustained pain resistant to previous medications) (containing morphine, oxycodone, ... (PDF/401.73 KB)
First published: 06/06/2011
Last updated: 06/06/2011
EMA/355008/2011
Modified release oral opioids - Article 31 referral - Annex I (PDF/581 KB)
First published: 06/06/2011
Last updated: 06/06/2011
Modified release oral opioids - Article 31 referral - Annex II (PDF/219.73 KB)
First published: 06/06/2011
Last updated: 06/06/2011
Modified release oral opioids - Article 31 referral - Annex IV (PDF/48.04 KB)
First published: 06/06/2011
Last updated: 06/06/2011
Modified-release oral opioids - Article 31 referral - Annex III (PDF/49.13 KB)
First published: 19/11/2010
Last updated: 06/06/2011
Questions and answers on the review of modified-release oral opioid medicines of the WHO level III scale for the management of pain - Initial (PDF/86.71 KB)
First published: 23/07/2010
Last updated: 23/07/2010
EMA/459105/2010
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
- Overview - lay-language summary of the stage of the procedure
- Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
- Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
- List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
- Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
- List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
- List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
- Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
- Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
- Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
- Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
- Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
- Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
- Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
- Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)
Note that older documents may have different titles.